X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AGMB-447 is an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). It is under phase 1 clinical development for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
Lead Product(s): AGMB-447
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AGMB-447
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
Proceeds will support Phase 2 candidate AGMB-129/ORG-129 for Fibrostenosing Crohn’s Disease and development of a highly innovative pipeline of anti-fibrotic and regenerative therapies, including AGMB-447 for idiopathic pulmonary fibrosis.
Lead Product(s): ORG-129
Therapeutic Area: Gastroenterology Product Name: AGMB-129
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: EQT Life Sciences
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing October 11, 2023
Details:
AGMB-129 (ORG-129) is an oral, small molecule GI-restricted inhibitor of ALK-5 (or TGFbR1) for the treatment of Fibrostenosing Crohn’s Disease. TGFb is a known master regulator of fibrosis and preliminary clinical data supports targeting the pathway in fibrotic indications.
Lead Product(s): AGMB-129
Therapeutic Area: Gastroenterology Product Name: AGMB-129
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
AGMB-129 (ORG-129) is an oral, small molecule GI-restricted inhibitor of ALK-5 (or TGFbR1) for the treatment of Fibrostenosing Crohn’s Disease. TGFb is a known master regulator of fibrosis and preliminary clinical data supports targeting the pathway in fibrotic indications.
Lead Product(s): ORG-129
Therapeutic Area: Gastroenterology Product Name: AGMB-129
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
Agomab’s pipeline consists of its lead candidate AGMB-129, a gastrointestinal tract restricted ALK-5 inhibitor for the treatment of fibrostenotic Crohn’s disease that is currently being investigated in a Phase 1 clinical trial in healthy volunteers.
Lead Product(s): ORG-129
Therapeutic Area: Gastroenterology Product Name: AGMB-129
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $114.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 13, 2022
Details:
The combined organization will focus on translating growth factor signaling pathways into innovative therapies including lead program, ORG-129, a gastrointestinal tract restricted ALK-5 inhibitor currently in a Phase 1 clinical trial.
Lead Product(s): ORG-129
Therapeutic Area: Gastroenterology Product Name: ORG-129
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Origo Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 28, 2021
Details:
Proceeds to further advance lead compound AGMB-101 and expand pipeline in inflammatory, metabolic and fibrotic diseases.
Lead Product(s): AGMB-101
Therapeutic Area: Immunology Product Name: AGMB-101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Redmile Group
Deal Size: $74.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 10, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
